Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)
Status:
Not yet recruiting
Trial end date:
2024-09-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the efficacy and safety of mepolizumab in
children and adolescents with hypereosinophilic syndrome (HES) who are receiving standard of
care (SoC) therapy.